Sanjay G. Patel, MD, presented “Take-Home Messages of AUA 2019” for the Grand Rounds in Urology audience in November 2019.
How to cite: Patel, Sanjay G. “Take-Home Messages of AUA 2019” November, 2019. Accessed Dec 2024. https://dev.grandroundsinurology.com/take-home-messages-of-aua-2019/
Take-Home Messages of AUA 2019 – Summary:
Sanjay G. Patel, MD, reviews some of the more salient updates pertaining to prostate cancer discussed at the American Urological Association’s 2019 Annual Meeting. He covers the following topics: reducing persistent opioid use following radical prostatectomy, results from a pivotal trial of an MRI-guided transurethral ultrasound ablation (TULSA) device, BRCA germline testing, findings from the CALGB 90601 trial, and molecular imaging for patients with biochemical recurrence.
ABOUT THE AUTHOR
Sanjay G. Patel, MD, completed his undergraduate training in Biomedical Engineering at
Vanderbilt University. He proceeded to complete medical school at Vanderbilt University in
Nashville, Tennessee, and urologic surgery training at Vanderbilt University Medical Center. After
completing a Society of Urologic Oncology Fellowship at the University of Chicago, he joined the
faculty as an Assistant Professor in the Department of Urology at the University of Oklahoma in Oklahoma City.
Dr. Patel treats all urologic cancers (adrenal, kidney, ureter, bladder, urethra, and testicular
cancer) utilizing open, laparoscopic, and robotic surgery techniques. He has a particular interest
in the use of minimally invasive robotic approaches to treat urologic malignancies and has
extensive robotic surgery experience. He oversees the Bladder Instillation Clinic, where patients’ bladders
are directly treated with immunotherapy and chemotherapy to treat superficial bladder cancer. He is also developing techniques to perform intracorporeal robotic urinary diversions,
where he is using minimally invasive robotic techniques to create bladders out of the
intestinal tract.
Dr. Patel works with the Department of Engineering at the University of Oklahoma to develop novel diagnostic and therapeutic technologies to treat urologic disease. He also has an interest in genetic and molecular profiling of cancers, and how that kind of profiling can be used to guide treatment of urologic cancer.
